Review of the Indian market of anti-tuberculosis drugs: focus on the utilisation of rifampicin-based products.
METHODS
There is a need to better understand the extent of the utilisation of rifampicin in the market, particularly in fixed-dose combinations (FDC).


OBJECTIVE
To review the Indian market of antituberculosis drugs, as this is the largest single market in the world of this therapeutic class.


METHODS
Review and analysis of the sales data proffered by the Indian market audit. Estimated data relating to public sector product usage were utilised in order to obtain a more complete scenario.


RESULTS
The use of rifampicin-based products is very important in the Indian market of anti-tuberculosis drugs. Particularly common is the use of FDCs, which represent 62% of anti-tuberculosis drugs sold in the private market.


CONCLUSIONS
The Indian market for anti-tuberculosis drugs is very large and well integrated. FDCs are widely used. In addition to double- and triple-drug FDCs, four-drug combinations have recently been introduced into the market. The Indian industry also exports raw materials and pharmaceutical specialities.
Catalani
E
E
Hoechst Marion Roussel, Milan, Italy.
D000904:Antibiotics, Antitubercular / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D000995:Antitubercular Agents / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D004338:Drug Combinations; D004345:Drug Industry / Q000191:economics*; D004363:Drug Utilization; D006801:Humans; D007194:India; D012293:Rifampin / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D014376:Tuberculosis / Q000188:drug therapy*
D000904:Antibiotics, Antitubercular; D000995:Antitubercular Agents; D004338:Drug Combinations; D012293:Rifampin